###### Strengths and limitations of this study

-   Potentially the first study to examine in-depth patient--provider communication among low-income African American patients with prostate cancer.

-   Longitudinal, multimodal qualitative approaches and informants, and quantitative data will facilitate a more holistic perspective and yield a rich understanding of the experiences of African American patients with prostate cancer.

-   Providers may demonstrate an increased awareness in communicating with patients as a result of being observed and interviewed, as well as patients interacting with providers.

-   Recruitment from two safety net settings and qualitative study design may limit generalisability of findings.

-   This comprehensive view will inform intervention development, in which community stakeholders will be engaged as cocreators (eg, collaborators) for maximum cultural fit and impact.

Introduction {#s1}
============

High-quality cancer care occurs in a responsive healthcare system, where providers practise patient-centred communication and patients are informed and engaged.[@R1] In such a context, each patient can expect to receive the most appropriate treatment for his condition and personal circumstances. This ideal, however, is often out of reach for one of the most marginalised groups in US society---African American men, who also experience a disproportionate burden of prostate cancer (PCa).

African American men have an approximately 60% higher incidence, are more likely to be diagnosed with aggressive disease and have more than twice the mortality due to PCa compared with White men in the USA.[@R2] Among the causes of excess mortality is failure to receive guideline-concordant treatment, in which men do not receive definitive treatment (eg, surgery and radiation) when it would be most beneficial (undertreatment).[@R5] In addition, overtreatment of low-risk disease (therapies that may not be beneficial yet have serious side effects) contributes to poorer quality of life. These practices are at odds with at least three of the US National Academy of Medicine's (formerly the Institute of Medicine) six indicators of quality of care: (1) patient-centred communication and shared decision-making; (2) healthcare aligned with patients' needs, values and preferences; and (3) evidence-based medical decisions.[@R8]

The nature and course of PCa and the array of treatment options present daunting communication challenges for patients and providers. First, neither surgery nor radiation has been found to be superior for survival.[@R9] Second, national PCa treatment guidelines (eg, the National Comprehensive Cancer Network) call for risk stratification of disease aggressiveness as low, intermediate and high,[@R10] and clinicians are advised to consider the combination of life expectancy and risk in differentiating 'appropriate' from 'inappropriate' treatment.[@R10] This information is then interpreted by patients and their families based on their own perspectives and priorities, as well as their histories of illness and healthcare. All of this can be extraordinarily difficult for patients to grasp and navigate, particularly in the face of multiple and often mutually exclusive treatment options.[@R12]

Furthermore, while patient-centred risk stratification aims to tailor treatment options to patient characteristics, aspects of patients' lives well beyond observable 'risk factors' can be critically relevant. Importantly, men with low-risk PCa (which may never be life-threatening) can be told that they have cancer which does not require immediate treatment. This means that the tests show their cancer is currently not life-threatening (unlikely to spread) such that they can avoid invasive treatment if offered 'active surveillance' (regular monitoring with periodic biopsies, prostate-specific antigen (PSA) blood tests and other testing). Patients considering this option must fully grasp the fact that they have a cancer that does not require immediate treatment, but since the cancer can change a protocol of periodic, uncomfortable procedures (eg, biopsies) must be followed. For some African American men, this taps into historical mistrust of the healthcare system and fear that a disease will be intentionally untreated, as in the well-known example of the Tuskegee study of untreated syphilis.[@R13] Alternatively, opting for active treatment (eg, surgery or radiation) can result in impotence or incontinence, a prospect which evokes considerable distress.[@R15] Various studies have noted that a PCa diagnosis and its treatment can be perceived as a threat to African American men's sense of masculinity, impacting communication and well-being.[@R16] Patient comprehension and integration of these complex issues are essential as only he can know which configuration best fits his individual needs and preferences.

Unfortunately, disparities in healthcare in general are most pronounced among patients with low health literacy, partially explaining racial disparities in some health outcomes.[@R20] Specifically in PCa, African American men with low health literacy have worse outcomes, including greater distress[@R21] and higher PSA level at diagnosis (indicative of more advanced disease),[@R22] which may reflect larger socioeconomic (eg, literacy, income, education) differences. Previous studies have noted significant disparities in PCa care among lower income and uninsured African American men,[@R23] and in low-resource settings (eg, public hospitals and other safety net systems),[@R25] where time constraints exacerbate communication barriers and degrade quality of care. Health literacy of patients with PCa impacts their ability to engage in shared decision-making.[@R28] Low health literacy level can limit patient understanding of complex treatment information and potential side effects, and can hinder patient participation in the decision-making process.[@R29] Importantly, patients' individual preferences and priorities must be communicated, enacted and facilitated in the decision-making process, as one size does not fit all in shared decision-making.[@R30] These challenges are further complicated by evidence that patients with PCa tend to rely heavily on providers' recommendations,[@R35] and PCa specialists tend to favour the treatment they deliver.[@R37] Moreover, an African American man seeking cancer treatment might wonder which poses a greater threat to him---medical care, or the disease itself. In this context and with limited resources, the path to effective communication between safety net providers and African American patients with PCa is fraught.

We seek to decode the constellation of societal, institutional and individual forces through an in-depth exploration of African American men's communication experiences in PCa care, as he moves from prostate biopsy to cancer diagnosis and treatment decision-making. Our research is broadly informed by the theory of cultural health capital (CHC) which elucidates the influence of fundamental social inequalities on clinical interactions, complicating patient-centred care and intensifying inequality.[@R38] Recognising the power of culture and social context that people implicitly draw on to make sense of their world,[@R39] including contending with illness and healthcare, our study is designed to describe African American men's experiences and cognitive perceptions, and to tap into patients and providers' subconscious assumptions, expectations, knowledge and practices. Based on our understanding of the structures and processes that hinder or enhance communication for African American men, we will identify prospects for intervention strategies with the potential to optimise the experience and contribute to improved outcomes.

Methods and analysis {#s2}
====================

Study design {#s2-1}
------------

From January 2017 through December 2020, we will conduct a longitudinal inductive qualitative descriptive study, specifically an ethnographic approach, with 25 newly diagnosed African American men and their providers to explore patient--provider interaction from PCa diagnosis through treatment decision. Ethnography is a qualitative research method central to sociology and anthropology and increasingly used in implementation science.[@R40] It involves immersive, on-the-scene learning in natural situations. For this study, we take a multiperspective approach (including direct observation of people's behaviour and environments, and in-depth interviews with informants from varying perspectives) that is ideal for generating rich accounts of patient--provider interactions,[@R42] and details of patients' care experiences and providers' way of framing treatment options and delivering care.[@R42] Importantly, observations illuminate dynamics that patients themselves may be unaware of and have difficulty surfacing. We use ethnography in accordance with the CHC framework to identify practices that lead to disparities, and to reveal how disparities are produced.[@R45] In two very different safety net hospital settings, we will examine components of CHC[@R38] including patients' health literacy, knowledge, control, trust, empowerment and interpersonal processes of care (eg, communication, decision-making and interpersonal style) using: (A) observations of clinic interactions in urology, radiation oncology and primary care when available; (B) in-depth interviews with patients and providers; (C) patient and provider surveys; and (D) field notes.

Settings {#s2-2}
--------

Our study is based in two safety net settings in California that vary in key system factors. At one public hospital (site A), patients are seen primarily by urology residents with attending physician supervision. In this setting, resident rotations afford little opportunity to establish ongoing trusting relationships. The second hospital (site B) is a public hospital with a large African American community. Three urologists provide ongoing care here and have a greater opportunity to establish long-term relationships with their patients.

Study participants {#s2-3}
------------------

We propose a final study sample of 25 African American men with PCa---a number that is reasonable for achieving thematic saturation, and feasible within the study scope. As few as four to five patients can be appropriate when investigating qualitative, ethnographic cases in detail[@R43]; and studies with multiple data sources (eg, observations and interviews) have achieved thematic saturation[@R46] with three to nine cases.[@R48] To achieve this final sample, we will recruit up to 80 African American men sent for biopsy, as we anticipate that 30%--40% of biopsies result in a PCa diagnosis, and should result in approximately 24--32 potential PCa cases.

Men who (A) self-identify as African American, (B) report they are able to speak English, (C) are between the ages of 35 and 80 years, (D) do not have a history of PCa, (E) have an elevated PSA test, (F) are recommended for a prostate biopsy, and (G) are not cognitively impaired will be invited to participate. We opted for recruitment prior to biopsy in order to capture subsequent patient--provider discussion at the time of a PCa diagnosis, establish patient rapport and to avoid both recruitment at a sensitive time (ie, during cancer diagnosis) and any potential for the recruitment procedures to prematurely reveal the PCa diagnosis. When introducing the study to eligible patients, we describe it as a research study about how doctors and patients talk about prostate biopsy results and next steps. There can be complicated information presented when receiving biopsy results. We want to learn if there are things we can do to improve their experience as a patient. Additionally, we inform patients that we will follow men to their appointments for up to 4 months, but potentially less, depending on plans for their healthcare in urology and what happens after the biopsy.

Recruitment and consent {#s2-4}
-----------------------

Urologists, radiation oncologists and primary care providers at each site will be notified of the study via letter/email in advance of any recruitment and asked if they are willing to participate should a patient of theirs enroll in the study. We will offer in-person meetings to answer questions. The chiefs and medical director at both sites will encourage their colleagues' participation, as they provided enthusiastic support for the study proposal. Additionally, we received letters of support from current resident physicians, urologists on staff and a nurse practitioner from our partnering sites. We acknowledge there may be inadvertent coercive participation due to hierarchy; therefore, we will acquire verbal consent prior to original participation (eg, clinic observations) and again prior to providers completing a survey and in-depth interview (described below).

Patient identification and recruitment will vary slightly by clinic site. At site A, the study team will identify eligible men by reviewing upcoming clinic appointments scheduled in the urology clinic. During the clinic day, the provider seeing the eligible patient in urology will be notified of a patient's eligibility and will have an opportunity to decline participation (eg, due to known cognitive impairment). During the clinic visit for eligible patients, the provider asks the patient if it is okay for a researcher to come and talk to them about a study. If the patient gives permission, we then approach the eligible patient for recruitment, verbally introduce the study, review the printed consent form with the patient, answer questions and obtain written informed consent. If a patient indicates he needs more time to consider participation, we will provide our telephone number so he can call to ask more questions, and we will get his permission to follow-up with him at his next appointment (eg, prior to the prostate biopsy). Our consenting process will be repeated at the next appointment. At site B, the chief of urology will identify eligible patients who are scheduled for upcoming prostate biopsy appointments, and will inform our team. Similarly, we then meet eligible patients at their scheduled biopsy appointment to verbally introduce the study, review the printed consent form with the patient, answer questions and obtain written informed consent prior to biopsy. If a patient at this site needs more time to consider participation, we will provide our telephone number and get his permission to follow-up with him prior to his appointment to receive biopsy results, to obtain written informed consent. If a patient is accompanied by a spouse, partner, caregiver or support person, we will obtain verbal informed consent from this companion, as they may be present during study procedures.

Procedures and measures {#s2-5}
-----------------------

On enrolment, we will collect sociodemographic data from patients, including detailed contact information (phone, email, secondary contact person) for optimal retention. Standard urology protocol requires that results are delivered in person whether benign or malignant, usually within 1--2 weeks after biopsy. A member of our team (the principal investigator or research assistant) will be present to observe and audio record appointments that distribute biopsy results (eg, diagnosis appointment). Men who are not diagnosed with PCa will be thanked for their time and released from the study. We will be transparent that they are no longer needed for this study as they will not have any follow-up appointments in urology for PCa screening; however, we will add that if they return for a repeat biopsy we will re-engage them. Men without a PCa diagnosis will not be included in the final study sample (n=25). Patients diagnosed with PCa will be followed at multiple clinic appointments relevant to PCa care until a treatment decision has been made (up to 2 months; see [figure 1](#F1){ref-type="fig"}). We will conduct observations of multiple clinic visits, two in-depth interviews and up to four surveys with patients, all corresponding with scheduled clinic appointments for patient convenience and for retention. While data will not purposefully be collected from patients' companions (eg, spouse, partner, caregiver or support person) their comments will be captured on audio recordings of observed clinic appointments and included in analyses if relevant. We will also conduct one in-depth interview and survey with each treating provider seeing enrolled patients.

![Data collection procedures.](bmjopen-2019-035032f01){#F1}

### Direct clinic observations {#s2-5-1}

Direct observation is used to study processes, procedures, activities or people in their lived environment.[@R52] We will observe outpatient clinic appointments in urology, radiation oncology and medical oncology for patients newly diagnosed with PCa and considering treatment options. Due to the importance of coordination in high-quality cancer care[@R8] and the active role primary care providers often play in cancer care,[@R53] we will also observe primary care provider appointments of enrolled patients. During clinic appointments, we will accompany enrolled patients as they see PCa specialists and primary care providers, remaining present but silent, audio recording the encounter and taking notes. On arrival, providers will be informed (or reminded) about the study purpose (eg, following patients newly diagnosed with PCa) and the observer (lead author, NRP) will remain a constant fixture in the urology clinic throughout the study period as a regular member of the clinic team. Deviation from providers' normal behaviour is less likely when observation is sustained for an extended period of time.[@R54] During direct observations, we will also take field notes[@R55] to capture the substance of what was done and said, non-verbal behaviours (eg, eye contact, forward lean to indicate attentiveness and nodding to indicate understanding) and any other notable aspects of the appointment, patient or provider.

### Patient interviews and surveys {#s2-5-2}

Once patients are consented and enrolled, we will administer a baseline survey shortly after diagnosis that captures sociodemographic characteristics, health literacy,[@R56] satisfaction with care[@R57] and interpersonal processes of care (eg, hurried communication, patient-centred decision-making, compassionate, and so on).[@R58] Up to three additional follow-up surveys will be completed after each clinic appointment that assesses communication,[@R59] satisfaction with care,[@R57] perceived personal control[@R60] and financial need. Repeated surveys can offer unique insights into the changing clinical portrait of patients' experience across various phases of cancer care.[@R61] For example, a patient's perception of patient-centred communication may improve (eg, better score) as they have repeated appointments during the decision-making process. To reduce literacy burden, we will verbally administer the survey that includes 46 questions; and each patient will receive a \$15 gift card immediately after completing each survey.

We will conduct two in-depth interviews with patients within 3 weeks of their observed diagnosis and treatment decision appointments. These interviews will take place in a private location at each clinic site, at a time convenient for patients (eg, patient already has a clinic appointment scheduled or patient is willing to return to the clinic at a convenient time). Patients will be asked to discuss their experience with the healthcare system and their current visits. We will then guide patients to reflect on what they know and understand from the clinical discussions about their diagnosis, treatment options and the decision-making process, and explore how these affect their interactions with the healthcare team, choice of treatment and their social support network. Parts of recorded observations will be replayed during the interview to aid in recall. Such 'stimulated recall' provides powerful and needed retrieval cues as clinical interactions are complex and conversation can be extensive.[@R62] If a participant seems distressed or upset during any part of the research process, we will proactively offer to take a break, resume the interview at another time or terminate the observation or interview altogether. If needed, participants will also be immediately referred to a psychologist or social welfare professional for counselling. During the last in-depth interview, we will also ask patients how they felt about being part of this study, including being observed and recorded. Patients will receive a \$35 gift card immediately after completing each interview. If all surveys (up to 4) and interviews (2 total) are completed, patients will receive a total of \$130 for study participation.

### Provider interviews and surveys {#s2-5-3}

Once all patient data collection is complete, each provider who is involved in treatment decision-making of enrolled patients will complete a brief survey that captures sociodemographic characteristics, years since completing medical training (eg, residency), medical specialty, communication self-efficacy[@R65] and health communication skills training received. Providers will then complete an in-depth interview. This timing is designed to avoid providers changing their care and communication practices based on their exposure to various survey and interview questions, and scenarios. We will ask providers about their strategies for communicating a PCa diagnosis, treatment options, potential side effects and decision-making; if and how they adapt their communication style for patient literacy; their expectations of patient involvement in decision-making; other people they believe should be involved in decision-making; impediments to treatment decision-making; and any reflections or relevant past experiences they have treating African American patients with PCa. Portions of recorded clinic observations will be replayed during the interview to elicit discussion and for recall, when relevant.[@R62] We will also ask providers about their perceptions of the extent to which the observer may have impacted the degree of engagement or content of the patient--provider conversation and dynamic. Providers will receive a \$75 gift card for completing the interview, which we feel is reasonable given lower response rates relative to the general population.[@R66] We recognise this incentive may not motivate providers to participate and they may decline the gift card; however, we know that some providers may appreciate the incentive to share treats with their team/office.

Analysis plan {#s2-6}
-------------

All direct observations and qualitative interviews will be audio-recorded and transcribed verbatim, and imported into Dedoose software for coding, searching and retrieving coded text and audio. Dedoose is a cross-platform application for analysing qualitative and mixed methods research with text, audio, spreadsheet data and more, and is efficient for team coding.[@R67] Field notes will also be typed up and imported into Dedoose. Analysis will be led by NRP with guidance by JKS and RJP; the entire team will be involved in data interpretation through sharing of emergent findings and theme summaries for discussion and feedback.

Using standard techniques based on grounded theory,[@R68] we will follow an iterative process of deductive (eg, concept driven, based on constructs)[@R71] and inductive (eg, text driven, allow themes to emerge)[@R71] thematic content analysis that involves examining and re-examining actions and meanings contained in the data to develop more refined codes and themes from all observations, field notes and in-depth interviews. This includes becoming immersed in the data through reading and re-reading, line-by-line coding and team discussions; finalising a codebook for significant concepts, and subsequent coding of themes and concepts; and identifying associations.

We will first develop a preliminary codebook of deductive codes (eg, provider inviting questions, patient interjecting questions, provider speaking over patient) based on CHC[@R38] that includes definitions of codes and examples which will be organised by data sources (observations, patient interviews, provider interviews). Direct observations and patient interviews will enable us to explore (1) how the dynamics of CHC play out from the patient's perspective; (2) how the provider's approach and other system characteristics impact key relational components of obtaining care and decision-making; and (3) how health literacy and culture may influence various aspects of the patient's experience. Central to CHC is the concept of power dynamics---does the provider take steps to share power with the patient, or does she/he limit patient access to power by speaking past the patient or dominating the direction of the conversation? We will identify salient dimensions of patient trust and power/powerlessness, and power-sharing dynamics in clinical interactions. In addition, components of patient--provider communication and decision-making will be used to analyse type of communication, roles in communication and decision-making process among patients and providers.[@R73] For example, to what extent are providers engaging (or NOT engaging) in directive or instructive communication (eg, provider focuses on what to do without asking opinions) or shared communication (eg, provider shares information adapting to patients' needs and preferences)? Similarly, what are patients' preferences for decisional support? To what extent are patients engaging in communication and decision-making that is passive (eg, patient listens to options passively taking in information), active on demand (eg, patient does not voluntarily intervene in communication, but will if invited by the doctor) or active (eg, patient is involved in exchange of information---asks questions, expresses concerns, raises issues, and so on)?[@R73] Importantly, patients vary in how they want to be involved in discussing and selecting treatments. Not all patients desire to take an active role in decision-making, but rather prefer a passive or 'delegators' role.[@R76] We will also explore who patients want to involve in their care and decision-making. Does the patient feel confident and express his needs or concerns? Do the patient and provider share knowledge, information, needs and concerns in order to arrive at a decision together? How do patients express concerns about their masculine identity? How might their perceived threat to masculinity have an impact on communication with family members, friends and healthcare providers? How might patient's perspective on masculinity influence treatment decision-making? We will note the range of variation and attempt to explain what accounts for those differences. To follow, inductive codes will be generated that reflect additional insights beyond CHC and models of communication,[@R1] and these new codes will be added to the codebook.

Two team members experienced in qualitative analysis will independently code three transcripts from clinic observations to see how the deductive codes work and what inductive codes arise. They will meet regularly to discuss coding strategies, and compare results in order to reach consensus about assigning a particular code to a given quote or text. This process will help populate and revise the codebook. The two researchers will repeat this process with three patient interviews, then three provider interviews, and three field notes, constantly going through an iterative process until we reach consistency. If needed, a third senior team member will be included in the discussion to resolve any disagreement between the two coders. Once the codebook is final, the researchers will code the remaining transcripts and work collaboratively to develop categories and identify themes that emerge. On reaching consensus on emerging themes, we will produce summaries of findings for discussion with the full research team.

These data will represent different perspectives. Given the multiple data sources (observations and interviews) and respondents (patients and providers), we anticipate some codes and themes are going to come up in one data source, but not another (eg, present in patient interviews, but absent in provider interviews); and some might come up in multiple or all data sources. To inform data integration and triangulation of multiple data sources and respondent groups (patients vs providers), we will note where codes are present versus missing in various data sources and groups, and explore convergence, complementarity and heterogeneity. We will also examine notable changes or evolution in codes and themes over time, as patients progress from diagnosis to treatment decision. To synthesise our multiple forms of qualitative data, we will follow a modified version of a six-step triangulation protocol developed by Farmer *et al*.[@R77] The first step, sorting, refers to identifying the key themes in each data source (ie, observations, patient interviews, provider interviews and field notes) and respondent group (ie, patients and providers) to compare similarities and differences for the presence (or absence) and frequency, meaning and examples. Then we will code the degree and type of convergence---including agreement (full agreement between sources and respondents), partial agreement (agreement on one but not another theme), silence (theme is absent in one) and heterogeneity (variation between elements of comparison).[@R77]

All survey data will be analysed using Statistical Package for the Social Sciences (SPSS) software V.25. Separate summary statistics for patients and providers will be calculated for categorical (number, percent, minimum and maximum) and continuous (mean, median, SD and range) variables to describe the study population. Repeated measures (eg, patient-centred communication scores) will be assessed for changes or improvements over time. Survey results will also be reviewed in the context of the qualitative data, which may confirm, conflict or elucidate survey data.

Potential challenges {#s2-7}
--------------------

Recruitment may be challenging due to insufficient numbers of African American patients. If enrolment lags at one site, we will (A) increase the sample size at the more productive site, (B) extend recruitment, and (C) add a third clinical site where our team has established prior research partnerships. We recognise physicians may serve as 'gatekeepers' and could bias and impact recruitment efforts.[@R78] In light of key urology leadership supporting our research proposal, we do not anticipate this being a problem, but we will monitor it closely. For any patients who are not comfortable being observed, we will leave the audio recorder on in the room and step out of the clinic appointment. This strategy is also useful to overcome scheduling issues, in which a team member may not be available to attend all enrolled patients' clinic appointments. In this case, the provider will be asked to audio record the clinic visit with an extra audio recorder stored at the site.

Patient and public involvement {#s2-8}
------------------------------

Our team's extensive work in community engagement in PCa disparities over the past 6 years contributed to the development and ideas of this study. Specifically, members of a PCa support group led by one of our team members (NRP), which was started 3 years before this study was funded, influenced the launch of this study, ideas for potential interventions and a robust plan to engaging community stakeholders. However, patients were not officially involved in the design, recruitment of conduct of this study. Once data collection is complete, we will convene a Community Advisory Team (CAT) of African American PCa survivors, some of whom may have been enrolled in this study, and other community members engaged in various initiatives, including the Prostate Health Support Group and the Prostate Cancer Action Network (of the San Francisco Cancer Initiative (SF CAN) (described below)). The CAT will meet monthly to interpret data collected in this study, and contribute to the development of the next phase of intervention development to ensure cultural fit. We will also disseminate study results, in lay language, beyond the CAT to the support group and the Prostate Cancer Action Network.

Ethics and dissemination {#s3}
========================

This study was approved by the University of California San Francisco Institutional Review Board (16-20126) and the Alameda Health System Institutional Review Board (IRB17-03311A). Our study is designed to examine the ways in which PCa diagnoses and treatment options are communicated to African American patients, and patients' treatment decision-making. The longitudinal design of this study will yield a rich understanding of the experiences of African American patients with PCa from diagnosis through treatment decision-making, and identify gaps in communication where additional support may be necessary. The collection of multimodal qualitative approaches (observations and interviews) and informants, and quantitative data will facilitate a more holistic perspective. This comprehensive view will inform next steps in intervention development, in which community stakeholders will be engaged as cocreators (eg, collaborators) in interpreting ethnographic findings for maximum cultural fit and impact. Research findings from synthesising all of the integrated information from this study will inform intervention development with the goal to help aid communication between patients and providers and close key gaps identified from our results.

Following study completion, findings will be written up for submission to scientific conference presentations and peer-reviewed journals for publication. A summary of findings will be presented to collaborating clinical sites and providers involved in the study. As the next pilot intervention phase of this research will include community engagement, we will also prepare a lay summary for dissemination to study participants and a community-based patient advisory board, and provide an opportunity for feedback and discussion on the next steps of this research.

This research will also inform current programmes in the community---specifically the SF CAN Prostate Cancer Task Force. SF CAN is a city-wide initiative to reduce cancer-related morbidity and mortality by harnessing the collective impact[@R79] across major healthcare systems, community coalitions and community members.[@R80] The SF CAN Prostate Cancer Task Force[@R81] is working collectively to support healthcare providers and engage African American men regarding decisions for the detection and treatment of PCa, to decrease the overtreatment of low-risk disease and undertreatment of aggressive disease and eliminate the disparity in PCa mortality for African Americans. Activities include a quality collaborative, continuing medical education, community engagement and education, navigation/coaching and survivorship support.
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